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A role for intracellular zinc in glioma alteration
of neuronal chloride equilibrium
S Di Angelantonio*,1,2, E Murana1, S Cocco1, F Scala1, C Bertollini1, MG Molinari1, C Lauro1, P Bregestovski3, C Limatola1,4
and D Ragozzino1,4
Glioma patients commonly suffer from epileptic seizures. However, the mechanisms of glioma-associated epilepsy are far to be
completely understood. Using glioma-neurons co-cultures, we found that tumor cells are able to deeply influence neuronal
chloride homeostasis, by depolarizing the reversal potential of γ-aminobutyric acid (GABA)-evoked currents (EGABA). EGABA
depolarizing shift is due to zinc-dependent reduction of neuronal KCC2 activity and requires glutamate release from glioma cells.
Consistently, intracellular zinc loading rapidly depolarizes EGABA in mouse hippocampal neurons, through the Src/Trk pathway and
this effect is promptly reverted upon zinc chelation. This study provides a possible molecular mechanism linking glioma invasion
to excitation/inhibition imbalance and epileptic seizures, through the zinc–mediated disruption of neuronal chloride homeostasis.
Cell Death and Disease (2014) 5, e1501; doi:10.1038/cddis.2014.437; published online 30 October 2014
Glioma-associated epilepsy is an established but poorly
understood phenomenon. Over 80% of glioma patients suffer
from seizures,1 often representing the first symptomatic
presentation of a tumor and possibly preceding it.2 It has
been extensively reported that glioma cells release glutamate
in the extracellular space, through the glutamate-cystine
transporter (system Xc), promoting proliferation and invasion
and causing neuronal death.3 Accordingly, increased gluta-
mate levels have been implicated in numerous seizure
disorders4 and contribute to epileptogenesis in glioma-
implanted rodents.5,6 Glutamate excess may cause the
alteration of neuronal chloride (Cl−) homeostasis and depo-
larize γ-aminobutyric acid (GABA) reversal potential (EGABA),
as a result of Cl− transporters dysfunction or disequilibrium.7
Indeed, a precise balance between NKCC1 and KCC2 activity
is necessary for inhibitory GABAergic signaling in the adult
central nervous system8 and its disequilibrium can cause
elevation of intracellular [Cl−] leading to switch of GABAergic
signaling from hyperpolarizing to depolarizing in epileptic
tissue,9,10 contributing to epileptogenesis.11–13
In this study, we investigated the mechanisms of glioma-
induced neuronal overexcitation using co-cultures of hippo-
campal and glioma cells.We report that glioma cells cause the
alteration of EGABA, through glutamate-receptor-dependent
zinc (Zn2+) accumulation, leading to KCC2-mediated Cl−
transport unbalance. Our study provides the molecular
mechanism of glioma-induced elevation in intracellular Cl−
and a complete model linking glutamate release by glioma
cells to glioma-related epilepsy.
Results
Glioma co-culture increases neuronal [Cl-]i by a gluta-
matergic mechanism. To address the effect of glioma cells
on neuronal Cl− equilibrium, we determined the reversal
potential of the currents evoked by GABA application in
mouse hippocampal cultured neurons. As shown in Figures
1a and b, co-culturing neurons with patient-derived glioma
cells (MZC)14 caused a rightward shift in the current–voltage
relationship of GABA-mediated responses, giving a positive
shift of EGABA from −73.9± 1.2 mV (control; n=124) to
− 52.1±1.6 mV (co-culture; n= 101, Po0.001).
In control neurons, EGABA was significantly below resting
membrane potential (RMP); conversely, in co-cultured neu-
rons, despite a small depolarization of resting potential
(Figure 1b), EGABA value was consistently more positive than
RMP, reverting the driving force for GABA-mediated currents
(Figure 1c). Similar results were observed also after a shorter
(4h) co-culture duration (EGABA=− 52.2±4.4 mV; n=18).
EGABA shift resulted from the increase in [Cl
−]i, as directly
demonstrated using a genetically encoded Cl-Sensor,15,16
which gave values similar to those calculated by Nernst
equation (Figure 1d).
To investigate the possible role of glutamate released by
glioma cells in EGABA depolarization, glutamate receptors
(GluRs) antagonists (D-(− )-2-Amino-5-phosphonopentanoic
acid (APV), 20 μM; 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo
[f]quinoxaline-7-sulfonamide disodium salt (NBQX), 10 μM)
were added to the co-culture medium. In this condition,
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glioma-induced EGABA depolarizing shift was prevented
(Figure 2a). Similar effects were observed when co-culture
experiments were performed in the sole presence of APV
(EGABA=−70.6± 1.96mV; n= 12, Po0.01) or NBQX
(EGABA=− 70.5±7.7; n=6, Po0.01), indicating that activa-
tion of both AMPA and NMDA receptors is necessary to cause
EGABA shift.
In addition, when the system Xc blocker sulfasalazine
(250 μM) was added to the co-culture medium, EGABA
depolarization was prevented (Figure 2a), showing that this
effect requires Xc-mediated glutamate release.
Moreover, acutely applied glioma-conditioned medium
(GCM) activated APV/NBQX-sensitive inward currents
(Figure 2b) in hippocampal neurons, confirming the presence
of GluRs agonists in GCM.17
Altogether, these data show that in the co-culture condi-
tions, glioma cells cause the depolarizing shift of Cl−
equilibrium potential in neurons, through glutamate release
and GluRs activation. Consistently, EGABA depolarization was
observed in neurons co-cultured with different human and
murine glioma cells, but not with astrocytes (Figure 2c, and
Supplementary Table S1), indicating a tumor-specific effect.
Glioma-induced EGABA depolarization is due to Cl

transporters unbalance. In cultured hippocampal neurons,
KCC2 and NKCC1 transporters participate in the regulation
of Cl− homeostasis. Indeed, the acute application of
furosemide (100 μM; 5–15min), the blocker of both transpor-
ters, caused a minor shift in neuronal EGABA. Conversely, the
specific blockers of NKCC1 (bumetanide; 10 μM; acutely
applied 5–15min) and KCC2 (R-(+)-butylindazone
dihydroindenyl-oxy alkanoic acid, DIOA; 20 μM; 1 h pre-
treatment plus continuous superfusion) shifted EGABA in
opposite directions (Figure 3a), indicating that, in our culture
conditions, both transporters actively regulate [Cl−]i.
The alteration of Cl− transporter activity is involved in
glioma-induced EGABA shift in co-culture. In fact, in co-cultured
neurons, furosemide, bumetanide or DIOA treatment aboli-
shed EGABA depolarization (Figure 3b). However, the acute
application of bumetanide reverted the glioma-induced effect
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Figure 1 Glioma co-culture increases basal [Cl−]i in mouse hippocampal neurons depolarizing EGABA. (a) Average I–V relation of GABA-activated currents recorded by
perforated patch in control (n= 24; purple circles) and glioma co-cultured (24 h,1 : 1 ratio; n= 18; green circles) neurons (12 DIV); typical traces recorded in control and co-
cultured neurons at indicated membrane potentials; (b) Left, distributions of EGABA in control (purple columns) and co-cultured neurons (green columns; average EGABA, control
−73.9± 1.2 mV, co-culture − 52.1± 1.6 mV; n= 124/101, Po0.001 ANOVA); Right, distributions of RMP in control (purple columns) and co-cultured neurons (green columns;
average RMP, control − 66.6± 0.7 mV, co-culture − 63.1± 0.9 mV; n= 124/101, Po0.05 ANOVA); (c) Driving force for GABA (RMP—EGABA) (control/co-culture as in (b);
n= 124/101; Po0.001 unpaired t-test); (d) basal neuronal [Cl−]i measured in neurons transfected with Cl-Sensor (control, [Cl−]i= 9.1± 1.2 mM, purple column n= 243;
co-cultures, [Cl−]i = 16.9± 4.1 mM; green column, n= 43), and calculated using Nernst equation (control, n= 124; co-culture, n= 101; Po0.001 unpaired t-test)
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(Figures 3b and c), hyperpolarizing EGABA. Conversely, DIOA
treatment significantly depolarized EGABA by itself, likely
occluding co-culture depolarizing effect (Figure 3b). These
data indicate that glioma-induced EGABA depolarization is due
to the unbalance of cation-chloride transporters activity, likely
due to KCC2 reduced function.
To disclose the effects of glioma co-culture on neuronal
KCC2 protein expression, we performed immunoblot experi-
ments, revealing that the level of transporter expression was
similar in control and co-cultured neurons (Figure 3d), thus
indicating that glioma-induced alteration of neuronal Cl−
homeostasis relies on functional KCC2 modulation, rather
than on changes in expression.
Glioma co-culture causes KCC2 impairment by increas-
ing intracellular Zn2+ in neurons. To investigate a possible
role of intracellular Zn2+ on glioma-induced EGABA shift,
18 we
used the membrane permeant Zn2+ chelator N,N,N′,N
′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN). TPEN
application (20 μM; 5–20min) caused the rapid recovery of
neuronal EGABA from glioma-induced depolarization
(Figure 4a). This result suggests that glioma-induced EGABA
shift can be ascribed to KCC2 inhibition, caused by neuronal
Zn2+ rise. Accordingly, when similar EGABA depolarization
was obtained blocking KCC2 with the selective antagonist
DIOA (20 μM; 1 h pre-treatment plus continuous superfusion),
acute TPEN application had no effect (Figure 4a).
Using FluoZin-based fluorescence determinations, we also
observed that basal intracellular Zn2+ was significantly higher
in co-cultured neurons in respect to control (Figure 4b).
Neuronal Zn2+ accumulation was prevented by APV/NBQX
application in the co-culture medium (Figure 4c), indicating the
requirement for GluR activation. Consistently, the application
of GCM or glutamate (20 μM) onto FluoZin-loaded neurons,
elicited an APV/NBQX-sensitive fluorescence increase,
rapidly reverting to basal level upon TPEN application
(Supplementary Figure S1 and S2).
To identify the source of Zn2+, we performed experiments in
the presence of tricine, a chelator of extracellular Zn2+. Tricine
treatment (1 mM, 24 h) did not abolish the effect of co-culture
on EGABA (Supplementary Table S2), indicating that extra-
cellular Zn2+ is not required for EGABA depolarization.
However, co-culture induced [Zn2+]i accumulation was not
observed (not shown). Noteworthy, tricine treatment caused a
reduction in basal Zn2+ both in control and co-cultured neurons
(n=41/59, control/co-culture; not shown). These results
suggest that extracellular Zn2+ chelation modifies neuronal
Zn2+ homeostasis, altering basal cytosolic Zn2+ level. To avoid
possible effects on intracellular Zn2+ homeostasis, experi-
ments with Zn2+ chelators were repeated reducing incubation
time (4 h), following the observation that 4 h tricine treatment
did not impair neuronal ability to release intracellular Zn2+ in
response to a glutamatergic stimulus (Supplementary Figure
S2). Consistently, tricine did not prevent the depolarizing effect
of 4 h co-culture on EGABA (Figure 4d). Conversely, when
intracellular Zn2+ was chelated (with FluoZin 5 μM, 4 h), co-
culture-induced EGABA shift was abolished (Figure 4d).
All together, these data indicate that Cl− disequilibrium in
co-cultured neurons is due to intracellular Zn2+-dependent
KCC2 impairment.
Zn2+-mediated EGABA shift requires Src/TrkB activation.
To disclose the mechanisms underlying Zn2+-mediated
EGABA shift, neuronal [Zn
2+]i was artificially increased through
perforated (by gramicidin) patch pipette loading. We pre-
liminarily verified the efficacy of intracellular Zn2+ loading
through perforated patch by fluorescence recordings; the
presence of ZnCl2 in the pipette solution caused a time- and
concentration-dependent fluorescence increase in FluoZin-
loaded neurons, indicating that, in our experimental
conditions, Zn2+ permeates through gramicidin pores
(Supplementary Table S3; Supplementary Figure S3). When
0.1 μM ZnCl2 was added to a BAPTA (5mM) containing
intracellular solution, giving a controlled free [Zn2+]i of
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Figure 2 EGABA depolarization is due to glutamate release by glioma cells.
(a) Inhibition of GluRs or transport prevents EGABA shift in co-cultured neurons; EGABA
in glioma co-culture either untreated (−58.2± 2.4; n= 35; green), in the presence of
APV (20 μM) and NBQX (10 μM) (−68.2± 2.3; n= 27; Po0.05, ANOVA; yellow), or
of Xc glioma glutamate transport system blocker, sulfasalazine (250 μM;
− 69.5± 6.0; n= 10; Po0.05, ANOVA; orange) (control EGABA.− 72.2± 2.6;
n= 15; purple). (b) GCM activates glutamatergic currents; Top, currents elicited in
hippocampal neurons by GCM are blocked by ionotropic glutamatergic antagonists
(NBQX 10 μM; APV 40 μM) and recover upon drugs washout; bottom, average
amplitude of GCM-induced current responses before and after treatment with NBQX/
APV (n= 14; yellow). (c) RMP (dark grey columns) and EGABA (light gray columns)
values in neurons co-cultured with different glioma cell lines; MZC (n= 101), U87MG
(n= 7), GL15 (n= 4), GL261(n= 10) and astrocytes (n= 7; *Po0.05, **Po0.01
versus control neurons, ANOVA). Notice that MZC co-culture caused slight RMP
depolarization (# Po0.05). Data and the corresponding estimated [Cl−]i, calculated
using Nernst equation, are reported in Supplementary Table S1
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~10 nM (Supplementary Table S3) EGABA promptly shifted to
more depolarized values (Figures 5a and b). Conversely,
EGABA remained stable with control intracellular solution
(calculated as~ 0.1 pM free [Zn2+]i, Figure 5a), or when free
[Zn2+]i was below 2 nM (n=7; Supplementary Table S3). This
time-dependent EGABA depolarization was not observed
when cultures were treated with the KCC2 blocker DIOA
(20 μM; 1 h pre-treatment plus continuous superfusion;
Figure 5a and Supplementary Table S4). In these conditions,
neurons displayed a depolarized EGABA, likely occluding the
effects of intracellular Zn2+ loading. Consistently, acute TPEN
application (15min; Figure 5b) rapidly reverted Zn2+-induced
EGABA depolarization on control neurons. These data indicate
that intracellular Zn2+ level rapidly and reversibly interferes
with Cl− equilibrium, through KCC2 activity modulation,
highlighting intracellular Zn2+ rise as the key step in glioma-
induced EGABA depolarization.
Several mechanisms have been proposed to explain KCC2
downregulation in hyperexcitability models,7,20,21 including the
phosphorylation of KCC2 residues by a number of different
kinases. To explore the mechanism of Zn2+-mediated EGABA
shift, we investigated the involvement of Src/TrkB-dependent
KCC2 tyrosine phosphorylation,20,21 as intracellular Zn2+ has
been reported to transactivate TrkB in a Src-dependent
manner.22 When hippocampal cultures were treated with TrkB
inhibitor K252A (200 nM; 1 h pre-application and perfused
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Figure 3 EGABA depolarizing shift depends on Cl
− transporters unbalance. (a) EGABA shift in 12 DIV cultured hippocampal neurons induced by acute application of KCC2 and
NKCC1 blocker furosemide (100 μM, 5–15 min; n= 9; pink), NKCC1 blocker bumetanide (10 μM, 5–15 min; n= 12, ##Po0.01 respect to control; cyan) and KCC2 blocker DIOA
(20 μM, 1 h pre-application and during the experiment; n= 13, ##Po0.01 respect to control; brown). Notice that furosemide, bumetanide or DIOA application was uneffective on
neuronal RMP; (b) Cl− transporters blockers abolish EGABA shift induced by glioma co-culture in hippocampal neurons; effect of co-culture on EGABA in neurons either untreated
(control, − 72.4± 1.4; n= 14; co-culture, − 53.4± 2.6; n= 9; Po0.05) or treated with furosemide (control, − 69.4± 4; n= 9; co-culture, − 73.2± 4.3; n= 18; P= 0.12),
bumetanide (control, − 86.3± 3.4; n= 12; co-culture, 82.8± 7.9; n= 9; ##Po0.01 respect to control) and DIOA (control, − 59.2± 2.6; n= 13; co-culture, − 52.8± 6.1; n= 11;
##Po0.01 respect to control) (unpaired t-test). (c) Acute bumetanide application reverts EGABA shift in co-culture. Traces and I–V relation from a single co-cultured neuron before
(purple circles) and following application of 10 μM bumetanide (cyan triangles; 5–15 min, n= 5). (d) Glioma co-culture does not alter neuronal KCC2 expression. Bottom, western
blot analysis of KCC2 expression in hippocampal neurons in control and after glioma cell co-culture (n= 6-9; ANOVA); top, representative immunoblots ofKCC2 (140 KDa) and
β-tubulin III (Tuj1, 60 KDa) expression in control and co-cultured neurons as indicated
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during the experiment), intracellular Zn2+ failed to depolarize
neuronal EGABA (Figure 5c and Supplementary Table S4).
Similarly, in the presence of Src kinase inhibitor PP2 (5 μM; 1 h
pre-application and perfused during the experiment), EGABA
shift due to intracellular Zn2+ loading was absent (Figure 5c
and Supplementary Table S4). Thus, Zn2+-induced EGABA shift
requires the integrity of Src/TrkB pathway.
Consistently, by western blots analysis, we demonstrated
that GCM treatment (15min) significantly increased neuronal
Src phosphorylation (Figure 5d). This effect was Zn2+
dependent, as it was prevented by TPEN application (20 μM,
15min pre-treatment and during GCM application, n= 6;
P= 0.92 with respect to TPEN, Figure 5e). Moreover, GCM
treatment significantly increased neuronal TrkB phosphoryla-
tion (Figure 5f).
Altogether, these data indicate that glioma-released factors
might alter neuronal Cl− homeostasis through Zn2+-induced
Src/TrkB-mediated KCC2 modulation, as illustrated in
Figure 6.
Discussion
We used co-cultures of hippocampal neurons and glioma cells
to unveil the mechanisms of glioma-induced hyperexcitability,
reporting that glioma cells depolarize neuronal EGABA,
increasing [Cl−]i and reverting the driving force for GABA-
mediated currents. Our results show that EGABA depolarization
relies on Zn2+-mediated KCC2 functional impairment, disclos-
ing the underlying mechanism: glioma-released glutamate
activates neuronal GluRs, causing neuronal intracellular Zn2+
risewhich, through Src/TrkB activation, reduces KCC2 activity,
leading to intracellular [Cl−] increase and EGABA depolariza-
tion. We conclude that gliomamight reduce neuronal inhibition
through Zn2+-mediated downregulation of KCC2 activity,
causing hyperexcitability.
In glioma-co-cultured hippocampal neurons, the current–
voltage relationship of GABA-mediated responses is shifted to
more depolarized potentials, compared with control, giving a
more depolarized EGABA. This indicates a higher basal
neuronal [Cl−]i in co-cultures, confirmed by an independent
estimation in neurons transfected with a YFP-based Cl−Sen-
sor. Although glioma co-culture induces a small neuronal
depolarization, the shift of EGABA is more relevant, resulting in
the inversion of the driving force for GABA-mediated currents.
According to previous studies, Cl− homeostasis in cultured
hippocampal neurons is determined by the activity of both
NKCC1 and KCC2.8 Indeed, we show here that both
transporters are expressed in control neurons and their
activity is required to maintain Cl− equilibrium as blocking
either NKCC1 or KCC2 leads to a shift in basal EGABA.
Conversely, in co-cultured neurons, NKCC1 activity is
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Figure 4 EGABA shift is dependent on intracellular Zn
2+ rise. (a) Co-culture-induced EGABA depolarization depends on Zn
2+-mediated KCC2 inhibition. Left, TPEN application
reverts co-culture induced EGABA shift (co-culture/TPEN,− 60.8± 1.9 mV;− 79.7± 3 mV; n= 16, Po0.01; control/TPEN,− 72.8± 1.9 mV;− 77.4± 3.8 mV; n= 14; P= 0.76;
paired t-test), but fails to rescue EGABA depolarization when KCC2 is blocked by DIOA (20 μM; DIOA − 53.5± 2.4 mV; plus TPEN − 55.3± 4.3 mV; n= 6; P= 0.78). Right,
traces from a single co-cultured neuron before and following TPEN (20 μM) treatment. (b) Co-cultured neurons have higher basal Zn2+. Fluorescence monitoring from FluoZin-3
loaded control (purple circles; n= 125) and co-cultured (green squares; n= 158) neurons exposed to TPEN. (c) Co-culture-induced intracellular Zn2+ rise (control, purple column,
n= 67; co-culture, green column, n= 98) is prevented by GluRs blockers (APV 20 μM; NBQX 10 μM, n= 24, yellow column ordinate as in b). (d) Effects of Zn2+ chelation on co-
culture-induced EGABA depolarization. EGABA shift was absent when neurons were co-cultured in the presence of the Zn
2+-sensitive dye FluoZin (5 μM), chelating intracellular Zn2+
(control, − 77± 3.8 mV; n= 8; 4 h co-culture − 47.7± 4.6 mV; n= 13; 4h co-culture plus FluoZin − 75± 3.5 mV; n= 13; Po0.01), while tricine (1 mM, added to the
co-culture medium, and washed during recordings, to avoid acute KCC2 inhibition mediated by extracellular Zn2+ removal19) was ineffective (control,− 72.1± 3.4 mV; n= 13; 4h
co-culture − 52.2± 4.4 mV; n= 17; 4 h co-culture plus tricine − 56.8± 3.3 mV; n= 6; P= 0.65; ##Po0.01 versus control cultures treated with tricine)
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apparently not balanced by KCC2-mediated Cl− extrusion and
transporter disequilibrium leads to an increase in neuronal
[Cl−]i. This picture is demonstrated pharmacologically by
the use of selective antagonists of Cl− co-transporters:
(i) furosemide, the blocker of both transporters, abolishes
EGABA shift, demonstrating the involvement of Cl
− transport;
(ii) the specific NKCC1 antagonist bumetanide reverts co-
culture-induced EGABA depolarization, demonstrating that Cl
−
accumulation requires the activity of NKCC1; (iii) neurons
treated with the specific KCC2 blocker DIOA display depolar-
ized EGABA, likely occluding the co-culture effect. Altogether,
these data support the proposal that in neurons, a new Cl−
equilibrium is established during glioma co-culture, character-
ized by higher [Cl−]i and caused by reduced KCC2 activity.
We provide evidence that glioma-induced KCC2 impair-
ment, observed in co-cultured neurons, is due to intracellular
Zn2+ rise.18 Indeed, intracellular Zn2+ chelation by TPEN
rapidly reverts co-culture-induced EGABA shift and basal [Zn
2+]i
is significantly higher in neurons after glioma co-culture.
The effect of neuronal Zn2+ rise on EGABA was directly
evaluated in experiments where intracellular [Zn2+] was artificially
increased from pico to nanomolar, as in pathological
conditions.23,24 The resulting Zn2+-dependent EGABA shift is
ascribable to KCC2 impairment, because it was absent when
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Figure 5 Intracellular Zn2+ modulates EGABA through Src and TrkB activation. (a) Bottom, EGABA is rapidly depolarized in cultured hippocampal neurons loaded with ~ 10 nM
free Zn2+ through the patch pipette (dark red circles; t= 0, − 79.6± 4.7 mV; t= 5′, − 58.8± 4.8 mV; n= 17; *Po0.05; **Po0.01, paired t-test), but not with standard EGTA-
containing intracellular solution (empty circles; free Zn2+= 0.1 pM; P= 0.54; n= 8). Top, in cultures treated with the KCC2 blocker DIOA (20 μM, 1 h pre-application and during
the experiment), EGABA was significantly depolarized at t= 0 with both intracellular solutions (dark red squares, free Zn
2 ~ 10 nM, − 47.5± 1.2 mV; n= 5; empty squares,
free+Zn2+= 0.1 pM, − 52.8± 6.1 mV, n= 6; ##Po0.01; respect to control, ANOVA ), and remained stable despite the intracellular Zn2+ loading. (b) TPEN application reverts Zn2+-
induced EGABA shift. Top, sample current traces from 10 nM free Zn
2+-loaded neuron, at start of recording (t= 0), 5′ after and following TPEN application (20 μM; 15′). Bottom,
Zn2+-induced EGABA depolarization at t= 0; 5′ and 20′ (n= 7, **Po0.01, ANOVA); dashed column represents EGABA after 15′ TPEN application (following 5′ Zn2+ loading;
n= 8, ##Po0.01 versus 20′, ANOVA-Tukey test). (c) Impairment of Zn2+-induced EGABA depolarization (ΔEGABA at t= 5′, 22.8± 3.8 mV, n= 9) in the presence of Src kinases
inhibitor (PP2, 5 μM, n= 9, Po0.01) or TrkB inhibitor (K252A, 200 nM; n= 7, Po0.01) (versus control, ANOVA). EGABA and RMP were depolarized in control following, K252A or
PP2 treatment as reported in Supplementary Table S4. (d) GCM increases Src phosphorylation. Top, typical immunoblot experiment; bottom, GCM treatment (15′) increases Src
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phosphorylation (BDNF represents positive control)
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KCC2waspharmacologically blockedbyDIOA. Indeed, the effect
of Zn2+ on EGABA is likely occluded by pharmacological KCC2
block, as DIOA treated neurons already show a depolarized
EGABA, which is, consistently, not rescued by TPEN application.
Glioma-induced alteration of neuronal Cl− homeostasis
likely depends on functional KCC2 block, rather than on
reduction of protein expression (see Lee et al.7). This view is
based on the unaltered expression of neuronal KCC2 after
glioma co-culture and on the rapid rescue exerted by Zn2+
chelation, demonstrating a dynamic modulation of Cl− trans-
port mechanisms. The functional modulation of KCC2 activity
has been observed both in physiological and pathological
models, such as prolonged post-synaptic spiking,25 brain-
derived neurotrophic factor (BDNF) stimulation26 and oxygen
glucose deprivation.18 Our data suggest that the mechanism
responsible for glioma-induced KCC2 inhibition relies on Zn2+-
mediated Src/TrkB activation. Indeed, Zn2+-induced EGABA
shift was prevented by the application of Src or TrkB kinase
inhibitors (PP2 or K252A). Consistently, GCM increased the
level of TrkB and Src phosphorylation in hippocampal cultures,
the latter effect being prevented by the Zn2+ chelator TPEN.
These results are in line with the notion that intracellular Zn2+
may transactivate TrkB by a neurotrophin-independent and
Src-dependent mechanism, as reported in models of intense
neuronal activity.22
In neurons, Zn2+-induced TrkB transactivation may mimic
BDNF-TrkB signaling, leading to KCC2 phosphorylation on
tyrosine residues27,28 and driving neuronal disinhibition.29 We
can speculate that co-culture induced EGABA depolarization
needs KCC2 phosphorylation on tyrosine residues because of
Zn2+-induced TrkB transactivation.
We report that glioma-induced EGABA shift requires the
release of glutamate in the extracellular space by glioma cells
and the consequent activation of neuronal ionotropic GluRs.
Indeed, the application of APV and NBQX during co-culture
prevents EGABA depolarization.
It is known that glutamate can induce intracellular Zn2+
increase through different mechanisms, including AMPARs
and Ca2+ channel-mediated influx or Ca2+-dependent intra-
cellular release.25,30 We observed that both APV and NBQX
abolished co-culture-induced EGABA depolarization highlight-
ing the role for both ionotropic GluRs in this effect. The
simplest explanation for this evidence is that AMPAR-
mediated neuronal depolarization drives NMDAR activation
thus allowing Ca2+-dependent intracellular Zn2+ release.30
Our data indicate that the source of Zn2+ is intracellular, as the
extracellular Zn2+ chelator tricine was ineffective, whereas
FluoZin prevented co-culture-induced EGABA depolarization.
It has to be considered that tricine treatment, although did
not prevent co-culture-induced EGABA depolarization, inhibited
co-culture-induced basal [Zn2+]i accumulation. Thus, perturb-
ing extracellular Zn2+ concentration may modify neuronal Zn2+
homeostasis, preventing cytosolic Zn2+ accumulation. How-
ever, tricine-treated neurons retained the ability to release
intracellular Zn2+ in response to a glutamatergic stimulus, and
this event is likely sufficient to trigger the intracellular signaling
leading to KCC2 impairment.
It is well established that intracellular Zn2+ rise induces cell
death, and Zn2+ exposure is toxic to neurons both in vitro and
in vivo. It is now evident that increased cytosolic Zn2+ resulting
from liberation from intracellular stores, rather than cytoplas-
mic influx of synaptically released Zn2+, can be highly toxic
during oxidative and other types of neuronal injury,31 and Zn2+
dyshomeostasis appears to be a common feature of numer-
ous neuropathological conditions.23,32 We speculate that the
reported mechanism, leading to reduced GABAergic trans-
mission, could underlie the etiology of glioma-related epilepsy,
pointing to Zn2+ accumulation as a possible therapeutic target
to restore KCC2 function and the excitatory/inhibitory balance.
In this view, it is possible to speculate that Zn2+ homeostatic
drugs may be helpful in the treatment of Zn2+-related
neurological disorders such as neuronal hyperexcitability or
Alzheimer’s disease.33
The use of co-cultures34 allowed to disclose the molecular
mechanisms involved in glutamate-mediated overexcitation
induced by glioma. Our results are in line with recent works
showing that Xc-mediated glutamate release is responsible for
the generation of tumor-associated epileptic events in glioma-
bearing mice.6,35 Indeed, increased concentration of extra-
cellular glutamate has been found in peritumoral tissue in both
humans and mice,6,36 supporting its role in tumor growth,
survival and peritumoral seizure activity.6 Additional sources
of glutamate in peritumoral tissuemay bemicroglial Xc system
or reverse activity of Na+-dependent glutamate transporters in
neurons or astrocytes.37,38 Thus, the co-culture system likely
retains the feature of excessive glutamate release typical of
glioma. Consistently, neuronal EGABA shift was observed in co-
culturing neurons with different glioblastoma cell lines, but not
with astrocytes, supporting the view of a tumor-specific effect.6
Glutamate-induced alteration of neuronal Cl− homeostasis
may act concomitantly with other mechanisms, including the
direct depolarizing effect of glutamate on neurons, displacing
the excitation/inhibition balance toward an increased network
excitability, thus promoting seizure onset.35
In conclusion, our study provides a possible explanation of
the mechanisms by which glioma cells affect neuronal Cl−
equilibrium, highlighting the role of Zn2+, recently emerged in a
variety of excitotoxic conditions, such as epilepsy, ischemia
and brain trauma.32
Neuron
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co-culture
-70 mV
Glioma Cell
glutamateXc
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NKCC1
GluRs
GABAAR
2
3
4
5
Src/TrkB6
KCC2
↑Cl-
Cl-
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Figure 6 Model of glioma-induced EGABA shift. Glutamate released from glioma
cells (1) causes GluR-dependent (2) neuronal [Zn2+]i increase (3), Src/TrkB-mediated
KCC2 inactivation (4) leading to [Cl−]i increase (5) and EGABA shift (6)
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Materials and Methods
Animals. Procedures using laboratory animals were in accordance with the
international guidelines on the ethical use of animals from the European
Communities Council Directive of November 24, 1986 (86/609/EEC). All efforts
were made to minimize animal suffering and to reduce the number of animals used
in accordance with the European Communities Council Directive of September 20,
2010 (2010/63/UE).
Primary hippocampal neuronal cultures. Hippocampal neuronal
cultures were prepared from newborn (P0-P1) C57BL/6 mice of either sex (Charles
River - Research Models and Services, Lecco, Italy). In brief, after careful dissection
from diencephalic structures, the meninges were removed and the hippocampi were
chopped and digested in 1.25 mg/ml trypsin for 20 min at 37 °C. Cells were
mechanically dissociated and plated at a density of 105 in poly-L-lysine-coated glass
coverslip (12 mm diameter) in serum-free Neurobasal Medium (Gibco Life Science,
Life Technologies Italia, Monza, Italy), supplemented with B27 2 mM L-glutamine
and 100 μg/ml gentamicin (neuronal culture medium). Then, cells were kept at 37 °C
in 5% CO2 for 10–13 days with medium replacement (1 : 1 ratio) three times per
week. With this method, we obtained cultures composed by 60–70% neurons,
30–35% astrocytes and 4–5% microglia, as determined with β-tubulin III, glial
fibrillary acidic protein and isolectin IB4 staining.38 The same procedure was
followed to prepare rat hippocampal culture used for some immunoblot experiments.
Glial primary cultures. Primary cortical glial cells were prepared from P0-P2
mice. Cerebral cortices were chopped and digested in 30 U/ml papain for 40 min at
37 °C and gently triturated. The dissociated cells were washed, suspended in
Dulbecco's Modified Eagle Medium (Gibco, Life Technologies Italia) with Glutamax
with 10% fetal bovine serum (Invitrogen, Life Technologies Italia) and plated at a
density of 9–10 × 105 in 175 cm2 cell culture flasks. At confluence (10–14 days
in vitro, DIV), glial cells were shaken for 2 h at 37 °C to detach and remove
microglial cells. These procedures gave almost pure astrocytes cell population
(4–6% of microglia contamination), as verified by staining with glial fibrillary acidic
protein and isolectin IB4.34
Neuronal culture transfection. Hippocampal neuronal cultures were
transfected at 9–10 DIV. One day before transfection, 50% of the culture medium
was replaced with fresh medium. For transfection, 100 μl of Neurobasal media were
mixed with 2 μl of NeuroMag (OZ Bioscience, Marseille, France) and 1 μg of Cl-
Sensor cDNA.15,16 The mixture was incubated for 15–20 min at room temperature
and thereafter distributed dropwise over the neuronal culture. Neuronal cultures
were placed on a magnetic board (OZ Bioscience) and incubated for 15 min (37 °C,
5% CO2). One hour later, 50% of neuronal culture medium was substituted with
fresh neuronal culture medium. Cells were used for experiments 24–76 h after
transfection.
Glioma cell culture. Patient-derived glioma cells (MZC; kindly provided by Dr.
Antonietta Arcella, Neuromed, Italy) within passage 40,14,39 glioblastoma cell lines:
GL15,14,40 U87MG (American Type Culture Collection, Rochville, MD, USA) and
GL26141 were grown in Dulbecco's Modified Eagle Medium with Glutamax
supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin G,
2.5 μg/ml amphotericin B and 100 μg/ml streptomycin at 37 °C in a 5% CO2
humidified atmosphere. Medium was changed three times per week; cells were
used between 20th and 40th passage.
Co-cultures. Glioma cells or astrocytes, prepared as above, were re-suspended
in neuronal culture medium and replated by seeding 105 cells onto 0.33 cm2
transwell cell-culture inserts (pore size 0.4 μM, Corning B.V. Life Sciences,
Amsterdam, The Netherlands), allowing traffic of small diffusible substances, but
preventing cell-to-cell contact. Transwell inserts were transferred into 24-well
cultures plates, containing 10–12 DIV primary hippocampal cultures in neuronal
culture medium.
Neuronal viability after 4 and 24 h of co-culture was evaluated as reported in
Supplementary Figure S4.
Patch-clamp recordings. Patch-clamp recordings were obtained using glass
electrodes (3–5 MΩ) filled with the following intracellular solution (in mM): 140 KCl,
2 MgCl2, 10 HEPES, 2 MgATP, 0.5 EGTA; pH 7.3, with KOH. Perforated patch-clamp
recordings with access resistances between 30 and 40 MΩ were obtained using
gramicidin D.42 Gramicidin, prepared every 2 h, was added to the pipette solution to
a final concentration of 50 μg/ml. During experiments, neurons were continuously
superfused with normal extracellular solution containing (in mM): 140 NaCl, 2.5 KCl,
2 CaCl2, 2 MgCl2, 10 HEPES-NaOH and 10 glucose (pH 7.3), added with
tetrodotoxin (0.2 μM), using a gravity-driven perfusion system, consisting of
independent tubes for standard and agonist-containing solutions, connected to a
fast exchanger system (RSC-100; Bio-Logic, Claix, France). All recordings were
performed at 24–25 °C. For I–V experiments, neurons were voltage-clamped at
− 70 mV with 6-s steps to each test potential; GABA (100 μM; 500 ms; every 30 s)
was applied 1 s after the voltage step onset. A linear regression was used to
calculate the voltage dependence of GABA-evoked current. EGABA was taken as the
intercept of this best-fit line for each cell. We minimized bicarbonate flux through the
GABAA channels, using an HEPES-buffered extracellular solution (nominally CO2-
and bicarbonate-free43,44), so that EGABA was an estimation of ECl. Membrane
currents, recorded with a patch-clamp amplifier (Axopatch 200B; Molecular Devices,
Foster city, CA, USA), were filtered at 2 kHz, digitized (10 kHz) and acquired with
Clampex 10 software (Molecular Devices). The stability of the patch was checked by
repetitively monitoring the input and series resistance during the experiment, and
recordings were discarded when any of these parameters changed by 410%.
Zn2+ loading through gramicidin pores. When indicated (Figure 5 and
Supplementary Figure S3), intracellular [Zn2+] was artificially increased in neurons
through the perforated patch, using a BAPTA-based intracellular solution (in mM:
140 KCl, 2 MgCl2, 10 HEPES, 2 MgATP, 5 BAPTA) supplemented with ZnCl2 (0.01–
100 μM). The corresponding free Zn2+ concentrations were calculated using the
MaxChelator software: http://www.stanford.edu/ ~ cpatton/maxc.html, and are
reported in Supplementary Table S3.
Zn+2 imaging. Fluorescence images were acquired at room temperature
(24–25 °C) using a customized digital imaging microscope. Excitation of
fluorophores at various wavelengths was achieved using a 1-nm-bandwidth
polychromatic light selector (Till Polychrome V), equipped with a 150 W xenon lamp
(Till Photonics, Hillsboro, OR, USA). Fluorescence was visualized using an upright
microscope (Axioskope) equipped with a 40x water-immersion objective (Achroplan
CarlZeiss, Oberkochen, Germany) and a digital 12 bit CCD camera system
(SensiCam, PCO AG, Kelheim, Germany). All the peripheral hardware control,
image acquisition and image processing were achieved using customized software
Till Vision v. 4.0 (Till Photonics). Changes in the intracellular Zn2+ level were
monitored using the high-affinity Zn2+-sensitive indicator FluoZin-3AM (Invitrogen).
Neurons were loaded by incubating coverslips for 45 min at 37 °C in 1 ml of HEPES-
buffered salt solution containing: 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM
MgCl2, 20 mM HEPES-NaOH and 15 mM glucose (pH 7.3), plus 5 mg/ml of bovine
serum albumin and 5 μM of FluoZin-3AM. For time-lapse recordings, FluoZin-3AM
was excited at 480 nm (emission filter D535/40 nm, dichroic mirror 505DCLP).
Zn2+ fluorescence changes are presented as ΔF/F0= (F− F0)/F0, or ΔFTPEN=
(F0− FTPEN)/FTPEN, where F is the current fluorescence intensity, F0 is the
fluorescence intensity before agonist application and FTPEN represents fluorescence
intensity after 5 min of TPEN application.
Cl− imaging. For non-invasive monitoring of [Cl−]i, cells were transfected with
CFP/YFP-based Cl-Sensor15 and the optic system equipped with an emission filter
D535/40 nm and a dichroic mirror 505DCLP (505 nm) was used. Cells expressing
Cl-Sensor were excited at 445 and 485 nm wavelengths alternatively (50 ms,
0.1 Hz). [Cl−]i changes are expressed as a ratio (R) of background-subtracted F445
and F485 (R= F445/F485). (Supplementary Figure S5) Calibration of Cl-Sensor
(Supplementary Figure S6) was performed as in Markova et al.15 and Wassem
et al.16 External solutions with different Cl− concentrations (in mM: 1, 3, 7, 12, 20,
35, 50, 70, 82.4, 130, 164.8) were obtained by mixing the following solutions (in
mM): (i) 164.8 KCl, 10 D-glucose, 20 HEPES, pH 7.32 and (ii) 164.8 K-gluconate,
10 D-glucose, 20 HEPES, pH 7.32. To increase the permeability of the cell
membrane to Cl− ions, β-escin (80 μM, Sigma, St Louis, MO, USA) was added to
the extracellular solution and applied during 2–5 min. Fluorescence signals
corresponding to rising Cl− concentrations were monitored from single Cl-Sensor
expressing neurons, after β-escin removal.
Glioma-conditioned medium (GCM). GCM was prepared as follows:
when cultures of glioma cells became confluent (~3 × 106 in 10 cm culture dishes),
the culture medium was substituted with 10 ml of filtered normal extracellular
solution. The conditioned medium (GCM) was collected after incubating for 4 h,
centrifuged, pH adjusted to 7.35 and then used for electrophysiological and imaging
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experiments.17 For immunoblot analysis of TrkB and Src activation, GCM was
obtained incubating (4 h) glioma cells in Locke’s buffer (in mM: 154 NaCl, 5.6 KCl,
3.6 NaHCO3, 2.3 CaCl2, 1 MgCl2, 5.6 glucose, 5 HEPES; pH 7.4).
Cell stimulation and western blot analysis. For western blot
experiments, 4 × 105 hippocampal cells were plated on poly-L-lysine coated
12-well cultures plates.45
For the analysis of TrkB and Src activation, cultured hippocampal neurons were
incubated for 2 h in Locke’s buffer and stimulated for 15 min with either GCM or drugs:
BDNF (100 ng/ml), platelet-derived growth factor (100 ng/ml). To assess the role of
Zn2+ rise in Src phosphorylation, hippocampal cultures were treated with the Zn2+
chelator TPEN (20 μM, 15 min pre-application, and during GCM stimulation).
Corresponding cell lysates were run on SDS-polyacrylamide gel and analyzed for Src
or TrkB phosphorylation. Densitometric analysis was performed with QuantityOne
software (Bio-Rad Laboratories S.r.l., Segrate (MI), Italy) and phosphoprotein levels
were normalized for TrkB and Src expression. For KCC2 expression determination,
western blot analysis was performed on rat hippocampal cell lysates in control
conditions and after 24 h co-culture with equal number of glioma cells. For each
condition, equal amounts of proteins were loaded on SDS-PAGE gel for immunoblot
analysis with rabbit anti-KCC2. Protein levels were normalized for TuJ1 expression.
Drugs. GABA, Bicuculline methochloride, Tetrodotoxin citrate, NBQX and D-APV
were purchased from Abcam Biochemicals (Cambridge, UK); Furosemide (100 mM
in dimethyl sulfoxide (DMSO)), Bumetanide (50 mM in EtOH) and PP2 (10 mM in
DMSO) were purchased from Tocris Biosciences (Bristol, UK); FluoZin-3AM
(Invitrogen, 5 mM DMSO); K252a (Calbiochem, Merck S.p.a., Milano, Italy); DIOA
(Santa Cruz Biotechnology, Inc., Heidelberg, Germany; 200 mM in EtOH); BDNF
(PeproTech EC Ltd., London, UK); TPEN (10 mM in EtOH), Gramicidin (50 mg/ml in
DMSO), Sulfasalazine (500 mM in DMSO), platelet-derived growth factor and all
chemicals used were purchased from Sigma-Aldrich, Milan, Italy. Where not
indicated, all drugs were dissolved in water. Antibodies were purchased and used as
follows: rabbit anti-Phospho TrkB (phospho Y515, 1 : 500, Abcam, Cambridge, UK),
rabbit anti-Phospho Src (phospho Y416, 1 : 2000, Abcam), mouse anti- Neuronal
Class III β-tubulin (TuJ1, 1 : 2000, n.cat MMS-435P, Covance, San Diego, CA, USA),
rabbit anti-actin (1 : 5000, Sigma-Aldrich); rabbit anti-KCC2 (1 : 1000; Millipore,
Temecula, CA, USA).
Drug Application. During electrophysiological and fluorescence measure-
ments, neurons were continuously superfused with normal extracellular solution,
using a gravity-driven perfusion system, consisting of independent tubes for
standard and agonist-containing (GABA, GCM) solutions, connected to a fast
exchanger system (RSC-100; Bio-Logic) positioned 50–100 μm from the cell.
Antagonists were usually acutely applied through a parallel tubes of the same
perfusion system. DIOA, K252A and PP2 were pre-incubated for 1 h (37 °C) and
then continuously applied during the experiments. Sulfasalazine, APV/NBQX,
BAPTA-AM and tetrodotoxin citrate were applied during co-culture in the co-culture
medium and not superfused during recordings (24 h). The values of EGABA and
RMP of control neurons, following different drug treatments are reported in
Supplementary Table S2 and Supplementary Table S4.
Data analysis. Data, analyzed offline, are presented as mean±S.E.M.; we
used the QuantityOne (Bio-Rad Laboratories S.r.l.) program for the densitometric
analysis of all immunoblots. Origin 7 (Origin software; Microcal Software,
Northampton, MA, USA) and Sigmaplot 11 (Systat Software Inc, London, UK)
software were used for statistical analysis. Paired and unpaired t-test and one-way
ANOVA were used for parametrical data, as indicated; Tukey test was used as post
hoc test; Mann and Withney test for non parametrical data. We constructed I–V
plots, cumulative distribution plots and fitted data points by linear or non-linear
regression analysis using Origin software. Statistical significance for cumulative
distributions was assessed with Kolmogorov-Smirnov test.
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